NCT04750759 (NICCAM) is a Phase 2 clinical trial of Niclosamide + Camostat in Covid19, sponsored by Charité Research Organisation GmbH.

Who is sponsoring NCT04750759?

NCT04750759 is sponsored by Charité Research Organisation GmbH.

What drugs are being tested in NCT04750759?

Interventions in NCT04750759: Niclosamide + Camostat, Placebo.

Is NCT04750759 still recruiting?

NCT04750759 is currently terminated. Last updated 9 December 2021.

Last reviewed 2021-12-09 · How we verify

NCT04750759: NICCAM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

Terminated Phase 2 Last updated 9 December 2021

What this trial tests

Phase 2 trial testing Niclosamide + Camostat in Covid19 in 4 participants. Terminated before completion.

Timeline

3 February 2021

Primary endpoint
29 October 2021

29 October 2021

Quick facts

Lead sponsor	Charité Research Organisation GmbH
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	4
Start date	3 February 2021
Primary completion	29 October 2021
Estimated completion	29 October 2021
Sites	1 location across Germany

Drugs / interventions tested

Niclosamide + Camostat — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Charité Research Organisation GmbH — full company profile →

Who can join

Adults 18 to 70, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Niclosamide (2000 mg QD) and Camostate (600 mg QID) are expected to be safe and well-tolerated as a combination therapy and to show clinically beneficial for COVID-19 patients.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K, Meyerholz DK, Bartlett JA, McCray PB. · · 2021 · cited 113× · PMID 34340553 · DOI 10.1128/mbio.00970-21
Niclosamide-A promising treatment for COVID-19.
Singh S, Weiss A, Goodman J, Fisk M, et al · · 2022 · cited 64× · PMID 35348204 · DOI 10.1111/bph.15843
The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
Mantzourani C, Vasilakaki S, Gerogianni VE, Kokotos G. · · 2022 · cited 18× · PMID 35072549 · DOI 10.1080/17460441.2022.2029843
Know your enemy and know yourself - the case of SARS-CoV-2 host factors.
Lee WS, Yousefi M, Yan B, Yong CL, et al · · 2021 · cited 10× · PMID 34488003 · DOI 10.1016/j.coviro.2021.08.007
COVID-19: The question of genetic diversity and therapeutic intervention approaches.
Figueiredo DLA, Ximenez JPB, Seiva FRF, Panis C, et al · · 2021 · cited 1× · PMID 35421211 · DOI 10.1590/1678-4685-gmb-2020-0452

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Charité Research Organisation GmbH trials

Trials by the same sponsor.

NCT04644705 — Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04750759 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charité Research Organisation GmbH
Last refreshed: 9 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04750759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing